References
- Bielekova B, Becker BL. Monoclonal antibodies in MS: mechanisms of action. Neurology. 2010;74:S31–S40.
- Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. Internet]. 2012 [cited 2018 Mar 21];380:1829–1839. Available from. ;(9856):. http://www.ncbi.nlm.nih.gov/pubmed/23122650.
- Cossburn MD, Harding K, Ingram G, et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology. 2013;80(1):55–61.
- Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819–1828.
- Coles AJ, Compston DA, Selmaj KW, et al. CAMMS223 Trial Investigators. Alemtuzumab vs. Interferon Beta-1a in early multiple sclerosis. N Engl J Med. Internet]. 2008 [cited 2018 Mar 21];359:1786–1801. Available from. http://www.ncbi.nlm.nih.gov/pubmed/18946064
- Wray S, Havrdova E, Snydman DR, et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. Internet]. 2019 [cited 2019 Dec 30];25:1605–1617. Available from. ;(12):. http://www.ncbi.nlm.nih.gov/pubmed/30289355.
- Comi G, Alroughani R, Boster AL, et al. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: pooled analysis of the CARE-MS, extension, and TOPAZ studies. Mult Scler. Internet]. 2019 [cited 2020 Mar 12];1352458519888610. Available from. ;. http://www.ncbi.nlm.nih.gov/pubmed/31762387
- Buonomo AR, Zappulo E, Viceconte G, et al. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. Internet]. 2018 [cited 2018 Oct 21];17(7):709–717. https://www.tandfonline.com/doi/full/10.1080/14740338.2018.1483330
- Rojas JI, Pappolla A, Patrucco L, et al. Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis? Mult Scler Relat Disord. 2020;39:101931.
- Higgins JPT, Sterne JAC, Savović J, et al. A revised tool for assessing risk of bias in randomized trials. Cochrane Methods Cochrane Database Syst Rev [Internet]. 2016 [cited 2020 May 6];10:52.
- Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. 2013 [cited 2020 May 6]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- de Castro BR, Sánchez RP, Martinez ST, et al. Alemtuzumab for relapsing multiple sclerosis in clinical practice: a four-year retrospective one-center study. Int J Risk Saf Med 2020;1–7.
- di Ioia M, Di Stefano V, Farina D, et al. Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: a report from a single Italian center. Mult Scler Relat Disord Available from. 2020;38:101504. cited 2019 Dec 30. Internet: https://linkinghub.elsevier.com/retrieve/pii/S2211034819304936
- Hyun J-W, Shin H-J, Jang H, et al. Therapeutic outcome of alemtuzumab in Korean patients with multiple sclerosis: 2-year follow-up. J Clin Neurol. Internet]. 2019 [cited 2020 Mar 13];15:328;(3): https://synapse.koreamed.org/DOIx.php?id=10.3988/jcn.2019.15.3.328
- Frau J, Coghe G, Lorefice L, et al. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. J Neurol. Internet]. 2019 [cited 2020 Mar 13];266(6):1405–1411. http://link.springer.com/10.1007/s00415-019-09272-6
- Kim H, Lee E-J, Kim SK, et al. Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients. Mult Scler Relat Disord. Internet]. 2019 [cited 2020 Mar 13];30:247–251. https://linkinghub.elsevier.com/retrieve/pii/S2211034819301063
- Chinea A, Honeycutt WD, Miller T, et al. Clinically insignificant effect of alemtuzumab infusions on vital signs: a prospective observational study in patients with relapsing-remitting multiple sclerosis. Int J MS Care. Internet]. 2019 [cited 2020 Mar 16];1537-2073. 2018–2076. http://ijmsc.org/doi/10.7224/1537-2073.2018-076
- Zappulo E, Buonomo AR, Saccà F, et al.Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 surface antigens.Open Forum Infect Dis.2019;cited 2019 Dec 30;611. Available fromhttps://academic.oup.com/ofid/article/doi/10.1093/ofid/ofz445/5601298
- Huhn K, Bayas A, Doerck S, et al. Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study. J Neurol. Internet]. 2018 [cited 2020 Mar 13];265(7):1521–1527. http://link.springer.com/10.1007/s00415-018-8871-2
- Prosperini L, Annovazzi P, Boffa L, et al. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. J Neurol. Internet]. 2018 [cited 2020 Mar 16];265(12):2851–2860. http://link.springer.com/10.1007/s00415-018-9070-x.
- European Medicines Agency, Pharmacovigilance risk assessment committee. Assessment Report for Lemtrada, 31 October 2019. [Internet]. [cited 2020 Apr 24]. Available from: www.ema.europa.eu/contact.
- Gaitán MI, Ysrraelit MC, Correale J. Neutropenia in patients with multiple sclerosis treated with alemtuzumab. JAMA Neurol. 2017;74(9):1143–1144.
- Yiannopoulou KG, Papadimitriou D, Anastasiou AI, et al. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion. Mult Scler Relat Disord. Internet]. 2018 [cited 2020 Jan 2];23:15–16. https://linkinghub.elsevier.com/retrieve/pii/S2211034818301330
- Raquel CC, Lucía TC, Carmen VM, et al. Cerebral toxoplasmosis in patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab. Mult Scler Relat Disord. 2020;39:101885.
- van Eijk M, Caster O. Unexpectedly high fatality rate in globally collected spontaneous reports of progressive multifocal leukoencephalopathy with alemtuzumab. 7th ISoP Annu Meet “Pharmacovigilance 21st Century.” Liverpool, UK, 15-18 October, 2017: Springer Science and Business Media LLC; 2017. p. 937–1045.
- Russo CV, Saccà F, Paternoster M, et al. Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis. Mult Scler J. Internet]. 2020 [cited 2019 Dec 30];26(1):123–126. http://journals.sagepub.com/doi/10.1177/1352458518813110
- Kukhon F, Silva-Cantillo D, Aladwan S, et al. Common infection mimics a tumor: legionella pneumonia presenting as a pulmonary mass. Am J Respir Crit Care Med. 2017;195:A4053.
- Spurgeon E, Abbatemarco J, Rensel M. A case of severe legionella pneumonia following the second treatment course of alemtuzumab infusion for relapsing remitting multiple sclerosis. Neurology. 2018;90 (15 Supplement) P5.352.
- Severe legionella pneumonia complicating alemtuzumab therapy for relapsing multiple sclerosis | C53. CRITICAL CARE CASE REPORTS: YOU GIVE ME (MORE) FEVER - INFECTION AND SEPSIS [Internet]. [ cited 2019 Dec 30]. Available from: https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A5293.
- Moiola L, Guerrieri S, Pisa M, et al. A case of listeriosis in a multiple sclerosis patient treated with alemtuzumab: a strict clinical and laboratory monitoring can help to make early diagnosis and avoid related meningitis. Mult Scler J. 2017;23:680–975.
- Verter ED, Hand J, Bagert B. Suspected Pneumocystis jirovecii pneumonia after alemtuzumab. Mult Scler J. Internet]. 2019 [cited 2020 Apr 28];23:680–975. Available from. ;:. . : http://journals.sagepub.com/doi/10.1177/1352458517731285
- Lau AY, Lui GCY, Chan KP, et al. Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis. Mult Scler Relat Disord. 2020;38:101503.
- Buonomo AR, Saccà F, Zappulo E, et al. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis. Mult Scler Relat Disord. Internet]. 2019 [cited 2018 Oct 21];27:44–45. Available from: https://www.sciencedirect.com/science/article/pii/S2211034818303572?via%3Dihub
- Yann K, Fran J, Nazar S, et al. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis. Mult Scler Relat Disord. 2017;14:1–3.
- Pappolla A, Midaglia L, Boix Rodríguez CP, et al. Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis. Neurology. 2019;92(6):296–298.
- Clerico M, De Mercanti S, Artusi CA, et al. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab. Mult Scler J. Internet]. 2017 [cited 2017 Dec 13];23(6):874–876. http://journals.sagepub.com/doi/10.1177/1352458516688350
- Barone S, Scannapieco S, Torti C, et al. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment. Mult Scler Relat Disord. Internet]. 2019 [cited 2018 Mar 19];92:6–8. http://www.ncbi.nlm.nih.gov/pubmed/29272733
- Boyle S, Olive G, Townell N, et al. Legionella longbeachae pneumonia as a complication of alemtuzumab therapy. J Clin Neurosci. Internet]. 2017 [cited 2018 Mar 20];46:67–69. http://www.ncbi.nlm.nih.gov/pubmed/28890039
- Haggerty P, Simms B, Kulla B, et al. Listeria meningoencephalitis and hydrocephalus complicating alemtuzumab therapy for multiple sclerosis – the first reported case in North America. SOJ Microbiol Infect Dis. 2018;6(1):1–9.
- Canham LJW, Manara A, Fawcett J, et al. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2018;24:38–41.
- Hradilek P, Hon P, Zeman D, et al. Listeria monocytogenes meningitis after course of alemtuzumab for relapsing-remitting multiple sclerosis - a case report. Mult Scler J. Internet]. 2017 [cited 2020 Apr 28];23:680–975. http://journals.sagepub.com/doi/10.1177/1352458517731285
- Rau D, Lang M, Harth A, et al. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis--report of two cases. Int J Mol Sci. Internet]. 2015 [cited 2015 Feb 11];16(12):14669–14676. http://www.ncbi.nlm.nih.gov/pubmed/26132570
- Penkert H, Delbridge C, Wantia N, et al. Fulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosis. JAMA Neurol. 2016;73(6):757.Internet]. [cited 2017 Dec 8]; Available from: http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2016.0146
- Sheikh-Taha M, Corman LC. Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis. Mult Scler J Internet]. 2017 [cited 2018 Jan 28];23(6):872–874. http://journals.sagepub.com/doi/10.1177/1352458517694431
- Mikulska M, Lanini S, Gudiol C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. Internet]. 2018 [cited 2018 Mar 19];24: S71–S82. http://www.ncbi.nlm.nih.gov/pubmed/29447988.
- Food and Drug Administration, Lemtrada: summary of product characteristics. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf. Last accessed 2018 Mar 20.
- Burkill S, Montgomery S, Hajiebrahimi MH, et al. Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012. Neurology. 2017;89(6):555–562.
- van Lunzen J, Altfeld M. Sex differences in infectious diseases-common but neglected. J Infect Dis. 2014;209(suppl 3):S79–S80.
- Bergamaschi R. Prognostic factors in multiple sclerosis. Int Rev Neurobiol. 2007;79:423-47.
- Holmøy T, Fevang B, Olsen DB, et al. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. BMC Res Notes. 2019;12(1):1–5.Internet]. [cited 2021 May 17
- Holmøy T, von der Lippe H, Leegaard TM. Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies. BMC Neurol Internet]. 2017 [cited 2017 Dec 9];17:65. Available from:. [];(1):. : http://www.ncbi.nlm.nih.gov/pubmed/28376817
- Matías-Guiu J, Montero-Escribano P, Pytel V, et al. Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab. Mult Scler Relat Disord. Internet]. 2020 [cited 2021 May 17];44:102297. www.elsevier.com/locate/msard
- Buonomo A, Brescia Morra V, Zappulo E, et al. COVID-19 prevention and multiple sclerosis management: the SAFE pathway for the post-peak. Mult Scler Relat Disord. Elsevier B.V. 2020;44: 102282.